Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33732382/
Multiple myeloma (MM) is the second most common hematopoietic malignancy and remains an incurable disease. Thus, novel drugs and therapeutic methods are required for patients with MM. The present study...
2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918236/
2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling...
Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma
Source : https://academic.oup.com/clinchem/advance-article-abstract/doi/10.1093/clinchem/hvab017/6168671
AbstractBackground. Due to improved treatment, more patients with multiple myeloma (MM) reach a state of minimal residual disease (MRD). Different strategies fo
miR‐17‐3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition
Source : https://doi.org/10.1002/ijc.33528
Kangdong Liu Corresponding Author China‐US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China Cancer Chemoprevention International Collaboration Laboratory,...